PEP-Therapy
Innovative peptides as targeted therapies for oncology
14 employees · est. 2014 · Paris, France
Pepkon
Pioneering breakthrough peptides for treating challenging cancers with precision and hope.
10 employees · est. 2022 · Paris, France
PEP-Therapy is the older company (2014 vs 2022); PEP-Therapy is the larger of the two.
Side-by-Side Comparison
| Metric | PEP-Therapy | Pepkon |
|---|---|---|
| Founded | ||
| Founded | 2014 older | 2022 |
| Headquarters | ||
| Headquarters | Paris, France | Paris, France |
| Employees | ||
| Employees | 14 larger | 10 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series A | Non Equity Assistance |
| Total Funding | ||
| Total Funding | $7.85M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 5 | 1 |
| Services | ||
| Services | Development and commercialization of peptide therapies for targeted oncology treatment | Peptide synthesis and testing, Drug optimization, Clinical trial advancement, Academic research collaboration, In-vivo and preclinical studies |
| Target Customers | ||
| Target Customers | Patients with various types of cancer, oncologists, pharmaceutical companies, research institutions | Pharmaceutical companies, Biotech researchers, Oncologists, Healthcare institutions, Cancer patients |
| Taxonomy | ||
| Taxonomy | Oncology, Clinical-stage, Targeted Therapies, Peptide-based Drugs, Cancer Research, Cell-penetrating Peptides, Pro-apoptotic Agents, Intracellular Delivery, Protein-protein Interactions, Phase Ia/b Clinical Trial, Metastatic Solid Tumors, Drug Development, Research Collaboration, International Investment | Cancer Treatment, Peptide Therapeutics, Precision Medicine, First-in-class Drug Development, Leukemia Treatment, Solid Tumors Treatment, Orphan Cancer Therapies, Pediatric Cancer Treatment, Pharmaceutical Research, Clinical Trials, Chronic Lymphocytic Leukemia (CLL), Thrombospondin-1 Peptides, Academic Research Collaboration, Oncology Innovation |
| Website | ||
| Website | pep-therapy.com | pepkon.fr |
About PEP-Therapy
PEP-Therapy is a clinical-stage biotechnology company founded in 2014 with a focus on developing innovative peptides as targeted therapies for oncology. Their first drug candidate, PEP-010, has shown promise as a pro-apoptotic agent with demonstrated anti-tumor efficacy in pre-clinical models and a...
About Pepkon
Pepkon, with its slogan "Pioneering breakthrough peptides for treating challenging cancers with precision and hope," is a French biotechnology startup established in 2022. The company’s primary focus is on developing first-in-class peptides aimed at treating cancers that are currently considered inc...
We will tell you when either one moves
BounceWatch watches PEP-Therapy and Pepkon for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at PEP-Therapy and Pepkon — by email.
Frequently Asked Questions
Compare PEP-Therapy with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at PEP-Therapy on 11 Jun 2025, and Pepkon on 23 Nov 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.